Clinical Trials Logo

Clinical Trial Summary

The purpose of this multicenter study is to evaluate a personalised and standardised exercise intervention for children and adolescents undergoing anti-cancer treatment.


Clinical Trial Description

In the randomised, controlled FORTEe trial, high evidence for an innovative, patient-centred exercise treatment shall be generated. Supervised exercise training intents to increase muscle strength and reduce muscular atrophy due to bedrest. CRF and HRQoL can be improved and in the future, these benefits may help to fight childhood cancer by increasing therapy efficiency and survival rate. Within the project, digital, innovative technologies such as augmented reality will be developed and applied to make the exercise training more effective, age-adapted and personalised. Moreover, FORTEe will stimulate translational research to provide access to paediatric exercise oncology as a new health care intervention. As a progress beyond the current state-of-the-art, FORTEe has the ambition to implement paediatric exercise oncology as an evidence-based standard in clinical care for all childhood cancer patients across the EU and beyond. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05289739
Study type Interventional
Source Johannes Gutenberg University Mainz
Contact Marie A. Neu, Dr. med.
Phone +49 (0) 6131 17 6828
Email marie.neu@unimedizin-mainz.de
Status Recruiting
Phase N/A
Start date April 25, 2022
Completion date August 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT03593525 - SPARK Symptom Screening and Feedback to Providers N/A
Completed NCT03650530 - The Family Talk Intervention in Pediatric Oncology N/A
Completed NCT02612025 - Effects of Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase N/A
Recruiting NCT05867186 - Fit to Fight Childhood Cancer
Completed NCT05691816 - The Experience of the Child With Cancer When Port à Cath Needle : Child's Speech
Completed NCT02085148 - A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Phase 1